跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00277732
NCT00277732已完成不适用

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

University Ghent1 个研究点 分布在 1 个国家目标入组 288 人开始时间: 2006年1月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
288
试验地点
1
主要终点
The difference between the study groups in the change of blood glucose and HbA1c
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to the control group ( = no input from pharmacist) or intervention group ( = with pharmaceutical care at baseline and follow-up visits over 6 months).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 75 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •45-75 years
  • •Body Mass Index >= 25
  • •Diabetes treatment for at least 12 months
  • •Regular visitors of the participating community pharmacy

排除标准

  • •Patients taking only insulin (no oral antidiabetic drugs)

结局指标

主要结局

The difference between the study groups in the change of blood glucose and HbA1c

时间窗: baseline and after 6 months

次要结局

  • Knowledge about diabetes and treatment(after 6 months)
  • Therapy adherence
  • Body Mass Index(after 6 months)
  • Periods of severe hypoglycemia
  • GP visits, emergency room visits and hospitalisations
  • Work days lost
  • Frequency of eye and foot examination

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

已完成
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCystic Fibrosis
NCT03911713Vertex Pharmaceuticals Incorporated77
已完成
2 期
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia Syndrome
NCT05633407argenx53
进行中（未招募）
1 期
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioChronic genotype 1 or genotype 4 Hepatitis C Virus infectionMedDRA version: 20.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 100000004862
EUCTR2015-003006-16-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57
进行中（未招募）
1 期
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioChronic genotype 1 or genotype 4 Hepatitis C Virus infectionMedDRA version: 20.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 100000004862
EUCTR2015-003006-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57
进行中（未招募）
1 期
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioChronic genotype 1 or genotype 4 Hepatitis C Virus infectionMedDRA version: 20.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 100000004862
EUCTR2015-003006-16-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57